Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

ClinicalTrials.gov ID: NCT01243944

Public ClinicalTrials.gov record NCT01243944. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of ruxolitinib (INC424) to Best Available Therapy (BAT) in participants with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).

Study identification

NCT ID
NCT01243944
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Incyte Corporation
Industry
Enrollment
222 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 26, 2010
Primary completion
Jan 14, 2014
Completion
Feb 8, 2018
Last update posted
Mar 5, 2019

2010 – 2018

United States locations

U.S. sites
28
U.S. states
18
U.S. cities
28
Facility City State ZIP Site status
Not listed Birmingham Alabama
Not listed Scottsdale Arizona
Not listed Pomona California
Not listed Sacramento California
Not listed San Diego California
Not listed Bridgeport Connecticut
Not listed New Haven Connecticut
Not listed Boynton Beach Florida
Not listed Fort Myers Florida
Not listed Jacksonville Florida
Not listed Winter Park Florida
Not listed Boise Idaho
Not listed Chicago Illinois
Not listed Lafayette Louisiana
Not listed Scarborough Maine
Not listed Baltimore Maryland
Not listed Columbia Maryland
Not listed Southfield Michigan
Not listed Jefferson City Missouri
Not listed St Louis Missouri
Not listed Omaha Nebraska
Not listed Morristown New Jersey
Not listed Somerville New Jersey
Not listed Charleston South Carolina
Not listed Greenville South Carolina
Not listed Nashville Tennessee
Not listed Houston Texas
Not listed Seattle Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 74 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01243944, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 5, 2019 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01243944 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →